Evonik revises outlook for 2024
General

Evonik revises outlook for 2024

Adjusted EBITDA expected between €1.9 billion and €2.2 billion

  • By ICN Bureau | July 17, 2024

In a difficult environment, Evonik has delivered another strong quarter, exceeding analysts' expectations. The company is therefore publishing preliminary key figures for the second quarter in advance and is materially raising its outlook for the fiscal year 2024.

Based on preliminary and unaudited figures, Evonik achieved an adjusted EBITDA of €578 million in the second quarter, 29 percent above the prior-year figure (Q2 2023: €450 million). Analysts had expected €531 million (Vara consensus as of May 29, 2024). At the same time, the result is another 11 percent higher than the already good first quarter.

As there was still no broad-based macroeconomic recovery, company-specific factors in particular led to this positive development: In addition to continued strict cost discipline, good volume development in Specialty Additives as well as a price recovery in Animal Nutrition and lower production costs were drivers of the sequential increase.

Based on this development, Evonik is raising its outlook for adjusted EBITDA, lifting the range for the full year 2024 by €200 million. Earnings are now expected to be between €1.9 billion and €2.2 billion (previously: €1.7 billion to €2.0 billion).

Following a slight decline in the first quarter, sales in the second quarter were, based on preliminary figures, at just above €3.9 billion and thus around the level of the previous year (Q2 2023: €3.9 billion).

The strict contingency measures led to lower costs across the Group. This had a positive impact on the adjusted EBITDA margin, which improved by 3.1 percentage points year-on-year to 14.7 percent (Q2 2023: 11.6 percent).

Upcoming E-conferences

Other Related stories

Startups

Chemical

Petrochemical

Energy

Digitization